Safety and Preliminary Efficacy of ANS-6637 to Reduce Drug Craving and Harm in People With Opioid Use Disorder
Status: Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 18 Nov 2019
Price : $35 *
At a glance
- Drugs ANS 6637 (Primary)
- Indications Opioid abuse
- Focus Adverse reactions; Proof of concept
- Acronyms SEARCH
- 18 Nov 2019 According to an Amygdala Neurosciences media release, the company has secured $5.6M financing which will be used to fund this trial.
- 17 Oct 2019 According to an Amygdala Neurosciences media release, this study is planned to initiate early next year.
- 25 Sep 2018 New trial record